PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis c |
| Phenotype | C0019158|hepatitis |
| Sentences | 45 |
| PubMedID- 22102387 | We classified pathological findings on chronic hepatitis in patients with chronic hepatitis c into minimal, mild, moderate, and severe chronic hepatitis, according to scheuer's scoring system,16 and assessed the effect of occult hbv infection of hepatitis c disease severity. |
| PubMedID- 23986848 | This 50-year-old man with chronic hepatitis due to hepatitis c virus infection suffered from recurrent episodes of hepatic encephalopathy since undergoing transcatheter arterial chemoembolization for hepatocellular carcinoma 1 year earlier. |
| PubMedID- 24678168 | [31] in 1988, 90% of cases of posttransfusion hepatitis were due to nanbh viruses which was later found out to be due to hcv. |
| PubMedID- 22684570 | Viral hepatitis b composed 85% of the viral hepatitis cases. |
| PubMedID- 23547075 | Underlying liver disease was hepatitis b in 38% of patients, hepatitis c in 38%, alcohol related in 25%, other in 14%, and none in 7%. |
| PubMedID- 22483477 | Experience of fibrosing cholestatic hepatitis with hepatitis c virus in kidney transplant recipients. |
| PubMedID- 25421584 | Viral hepatitis: cure of chronic hepatitis c--required length of follow-up. |
| PubMedID- 25091289 | Methods: a total of 343 chronic hepatitis patients infected with hepatitis c virus (hcv) genotype 2 (2a: n = 195; 2b: n = 148) were enrolled in this study. |
| PubMedID- 25848483 | In cases with persistent hepatitis due to failure of hepatitis c virus eradication, or chronic liver disease, such as nash, the treatment of which remains unestablished, it is important to reduce serum alanine aminotransferase levels and prevent liver fibrosis and development of hepatocellular carcinoma. |
| PubMedID- 21410059 | Non-invasive evaluation of liver fibrosis using acoustic radiation force impulse imaging in chronic hepatitis patients with hepatitis c virus infection. |
| PubMedID- 25338946 | Methods: we prospectively investigated the efficacy and safety of simeprevir in combination with pegylated interferon and ribavirin in five patients undergoing living donor liver transplantation (ldlt) with recurrent hepatitis due to hepatitis c virus (hcv) genotype 1b. |
| PubMedID- 22826750 | Seroprevalence of hepatitis a in patients with chronic hepatitis c in isfahan province. |
| PubMedID- 22440563 | Many chronic hepatitis patients with hepatitis c virus (hcv) are observed to have a degree of steatosis which is a factor in the progression of liver diseases. |
| PubMedID- 20376093 | hepatitis: treatment of chronic hepatitis c-how much interferon is enough. |
| PubMedID- 24631902 | Prospective evaluation of fibrotest(r), fibrometer(r), and hepascore(r) for staging liver fibrosis in chronic hepatitis b: comparison with hepatitis c. |
| PubMedID- 21468126 | Viral hepatitis: treating hepatitis c in children: an open horizon. |
| PubMedID- 22388028 | Appropriateness of hepatitis a vaccination in patients with hepatitis c. |
| PubMedID- 23923349 | The coexistence of occult hepatitis b with hepatitis c infection is of particular importance because of its added co-morbidity of liver enzymes elevation, increased severity of liver disease and increased risk of hepatocellular carcinoma. |
| PubMedID- 24953911 | Effect of hepatitis b vaccination in patients with chronic hepatitis c. |
| PubMedID- 25146854 | The uk is engaged in much hepatology research, but there are areas where the burden is great and may require greater focus, such as hepatitis e, development of a vaccine for hepatitis c, and further research into hepatitis-associated cancers. |
| PubMedID- 25764673 | [guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis c virus infection for the fiscal year 2014 in japan]. |
| PubMedID- 26195123 | 1distribution of patients included in the studytable 1baseline characteristics of patients in the treatment and control groupscharacteristicsindomethacin group(n = 82)glycerin group(n = 84)pfemalemale51 (62.19 %)31 (37.80 %)59 (70.23 %)25 (29.76 %)0.273age (years)51.59 ± 18.5554.0 ± 17.850.394outpatients46450.74hospitalized3639without comorbidity56540.427comorbid conditions2630 diabetes mellitus type 21214 hypertension77 dyslipidemia22 hypothyroidism10 copd11 hepatic cirrhosisa12 ischemic heart disease11 hiv01 asthma12normal total bilirubin pre-ercp26240.660elevated total bilirubin pre-ercp5660previous cholecystectomy42400.643dilated bile duct by imaging studies pre-ercp56620.506post-ercp diagnostics0.35 choledocolithiasis3432 begin biliary stenosis and/or leakage1814 suspected sphincter of oddi dysfunction1215 normal cholangiogram and/or pancreatogram811 malignant biliary tract stenosis89 pancreatic fistula23pre-ercp amylase level (u/l)57.39 ± 21.5655.36 ± 20.770.540aetiology in the indomethacin group: chronic hepatitis due to hepatitis c virus in 1 patient. |
| PubMedID- 25755401 | Background and aim: pegylated-interferon-alfa (peg-ifn-alpha) with ribavirin is an established treatment in chronic hepatitis due to hepatitis c virus (hcv) (ch-c). |
| PubMedID- 22098550 | Risk factors include chronic hepatitis b (estimated prevalence of 12%), chronic hepatitis c (at least 2% prevalence), and heavy consumption of alcohol among men. |
| PubMedID- 25778685 | Methods: chronic hepatitis patients with genotype 1b hepatitis c virus (hcv) infection showing serum hcv-rna levels greater than 5 log iu/ml received oral administration of cholecalciferol (2000 iu/day) or alfacalcidol (0.5 mug/day) for 4 weeks, and then they were given pegylated interferon (peg-ifn)-alpha2a plus ribavirin therapy in combination with either vitamin d3 for 48 or 72 weeks according to the response-guided manner. |
| PubMedID- 24223461 | 44 of these 50 hcc patients had cirrhosis, among which 42 cases with hepatitis b, one case with hepatitis c, and one case with hepatitis b and hepatitis c coinfection. |
| PubMedID- 21633525 | Mallory-denk bodies (mdb) are important as investigators, suggesting mdb as an indicator of the histologic severity of chronic hepatitis, causes of which include hepatitis c, primary biliary cirrhosis (pbc), and nonalcoholic fatty liver disease (nafld). |
| PubMedID- 25125954 | Methods: all chc patients from the hepnet.greece, an ongoing nationwide cohort study on viral hepatitis, with known hepatitis c virus (hcv) genotype who received treatment with peg-ifna and ribavirin were analyzed. |
| PubMedID- 20433036 | Conclusions: the strong association of alcohol use, hiv, and hepatitis b with hepatitis c, as well as the frequent occurrence of these conditions, indicates that targeted interventions for mitigating the potential effect of these exposures may present an efficient means of limiting progression of hepatitis c-related liver disease and reducing the population burden of hepatitis c mortality. |
| PubMedID- 22443693 | Antimitochondrial antibody -m2 positive autoimmune hepatitis during standard of care for chronic hepatitis c. |
| PubMedID- 26187292 | However, the enrolled subjects in some studies have also included chronic hepatitis b patients with chronic hepatitis c coinfection or other etiologies of liver diseases. |
| PubMedID- 20347177 | Background & aims: progressive deposition of liver fibrosis is a common feature of chronic hepatitis associated with hepatitis c virus (hcv) infection, and it may eventually lead to cirrhosis and liver failure. |
| PubMedID- 25742285 | Liver biopsy is routinely used to diagnose and stage the severity of hepatitis in patients with chronic hepatitis c [3], but has the drawbacks of invasiveness, sampling error and inherent risks [4]. |
| PubMedID- 21505755 | Additionally, we searched for other viral infections, including hepatitis b (with hbsag test), hepatitis c (with anti-hcv abs test), and cytomegalovirus (cmv, with pp65ag test). |
| PubMedID- 24063897 | Chronic hepatitis due to the hepatitis c virus (hcv) infection affects nearly 180 million people worldwide. |
| PubMedID- 22658873 | Background: the recommended standard therapeutic regimen for chronic hepatitis patients with hepatitis c virus (hcv) genotype 3 is pegylated interferon plus ribavirin for 24 weeks. |
| PubMedID- 20843308 | Serological and molecular expression of hepatitis b infection in patients with chronic hepatitis c from tunisia, north africa. |
| PubMedID- 22836284 | Background: chronic hepatitis because of the hepatitis c virus (chc) is a major health problem that can lead to decompensated cirrhosis, hepatocellular carcinoma, and eventually death, all of which are associated with significant healthcare costs. |
| PubMedID- 20677344 | Aim: to evaluate the overlap of autoimmune hepatitis in hepatitis c virus (hcv)-infected patients with intense interface hepatitis. |
| PubMedID- 21677334 | Chronic alcohol abuse (29%) and chronic hepatitis due to hepatitis c virus (hcv) infection (20%) were the most common causes of cirrhosis. |
| PubMedID- 23986831 | This 60-year-old man suffered from chronic hepatitis due to hepatitis c virus infection since undergoing a right hepatic lobectomy for hepatocellular carcinoma 5 months earlier. |
| PubMedID- 23316217 | Viral hepatitis with hepatitis c virus or hepatitis b virus and chronic liver disease such as alcoholic or nonalcoholic steatohepatitis are critical factors in the development of hepatocellular carcinoma (hcc). |
| PubMedID- 22186743 | Soluble urokinase plasminogen activator receptor in chronic hepatitis due to hepatitis c virus. |
| PubMedID- 26183636 | Fulminant hepatitis due to acute hepatitis c virus (hcv) infection is rarely observed. |
| PubMedID- 23999322 | Viral hepatitis: treating hepatitis c in injection drug users. |
Page: 1